Nevro Corp. is a global medical device company. The Company focuses on providing products that improve the quality of life of patients suffering from chronic pain. The Company has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. Its HF10 therapy is designed to deliver neuromodulation solutions for treating chronic pain. HF10 therapy enables patients to achieve sustained pain relief without paresthesia, thus enabling its patients to avoid the uncomfortable shocking or jolting sensations commonly associated with paresthesia. HF10 therapy relies on consistent anatomical lead placement. As of December 31, 2016, it was investigating the use of HF10 therapy to address additional indications, such as chronic upper limb and neck pain, painful neuropathies and non-surgical refractory back pain. The Senza system is approved to create electrical impulses from 2 hertz (Hz) to 10,000 Hz.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Medical Equipment, Supplies & Distribution - NEC
- Sub-Industry: N/A
- Symbol: NYSE:NVRO
- CUSIP: N/A
- Web: www.nevro.com
Capitalization:- Market Cap: $2.56 billion
- Outstanding Shares: 29,295,000
Average Prices:- 50 Day Moving Avg: $77.55
- 200 Day Moving Avg: $85.35
- 52 Week Range: $65.82 - $106.93
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: 1,747.00
- P/E Growth: -3.41
Sales & Book Value:- Annual Revenue: $255.29 million
- Price / Sales: 10.02
- Book Value: $8.29 per share
- Price / Book: 10.54
Profitability:- EBIDTA: ($25,290,000.00)
- Net Margins: -14.49%
- Return on Equity: -14.50%
- Return on Assets: -8.50%
Debt:- Debt-to-Equity Ratio: 0.58%
- Current Ratio: 11.91%
- Quick Ratio: 9.43%
Misc:- Average Volume: 782,421 shs.
- Beta: -0.73
- Short Ratio: 7.44
Frequently Asked Questions for Nevro Corp. (NYSE:NVRO)
What is Nevro Corp.'s stock symbol?
Nevro Corp. trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVRO."
How were Nevro Corp.'s earnings last quarter?
Nevro Corp. (NYSE:NVRO) posted its quarterly earnings results on Monday, May, 8th. The company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.26) by $0.24. The company had revenue of $68.40 million for the quarter, compared to analyst estimates of $68.71 million. Nevro Corp. had a negative return on equity of 14.50% and a negative net margin of 14.49%. The business's revenue for the quarter was up 64.0% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.33) earnings per share. View Nevro Corp.'s Earnings History.
Where is Nevro Corp.'s stock going? Where will Nevro Corp.'s stock price be in 2017?
9 brokerages have issued 12-month target prices for Nevro Corp.'s stock. Their forecasts range from $85.00 to $120.00. On average, they anticipate Nevro Corp.'s share price to reach $103.89 in the next year. View Analyst Ratings for Nevro Corp..
What are analysts saying about Nevro Corp. stock?
Here are some recent quotes from research analysts about Nevro Corp. stock:
- 1. According to Zacks Investment Research, "Nevro Corp. is a medical device company. It engages in developing and commercializing a neuromodulation platform for the treatment of chronic pain. The Company provides pain relief to the customers suffering from low back pain and types of chronic pains. Nevro has developed and commercialized the Senza (R) spinal cord stimulation (SCS) system for the treatment of chronic pain. Senza, HF10, Nevro and the Nevro logo are trademarks of the company. Nevro Corp. is headquartered in Menlo Park, California. " (6/3/2017)
- 2. Northland Securities analysts commented, "The widely awaited release of Boston Scientific's ACCELERATE Study data on the Q4 call today, was a downer. Strangely enough, the company stated on its call that it "would continue enrolling patients in the trial, expects enrollment to finish by end of FY17, and data release by mid-2018." Suffice it to say, the anti-climax will be perceived as something being off in the ACCELERATE Study, hence being positive for Nevro."The analyst speculated that something is off in the ACCELERATE study, causing a delay in datarelease. Here are some thoughts / questions:Is Boston Sci increasing the sample size in the trial ?Was there a sub-group analysis done and investigators realized that the bellcurve on lead placements was not on T8 - T10 locations, hence pain relief was sub-optimal? Will there now be more anatomical placement on T8 - T10 with its HF arm? In essence, is Boston Sci converging on Nevro's "secret sauce" (2/2/2017)
Who are some of Nevro Corp.'s key competitors?
Some companies that are related to Nevro Corp. include VWR Corp (VWR), Integra LifeSciences Holdings Corporation (IART), NuVasive (NUVA), ICU Medical (ICUI), LivaNova PLC (LIVN), Neogen Corporation (NEOG), Haemonetics Corporation (HAE), Inogen (INGN), Halyard Health (HYH), MiMedx Group (MDXG), CONMED Corporation (CNMD), K2M Group Holdings (KTWO), Asante Solutions (PUMP), Cardiovascular Systems (CSII), OraSure Technologies (OSUR), Orthofix International N.V. (OFIX), Intersect ENT (XENT) and AtriCure (ATRC).
Who are Nevro Corp.'s key executives?
Nevro Corp.'s management team includes the folowing people:
- Rami Elghandour, President, Chief Executive Officer
- Andrew H. Galligan, Chief Financial Officer
- Patrick Schmitz, Vice President - Operations
- Michael Enxing, Vice President of Sales
- Douglas A. Alleavitch, Vice President - Quality and Operations
- Christopher Christoforou, Vice President - Research and Development
- Ali Behbahani M.D., Independent Director
- Lisa D. Earnhardt, Independent Director
- Frank M. Fischer, Independent Director
- Wilfred E. Jaeger M.D., Independent Director
Who owns Nevro Corp. stock?
Nevro Corp.'s stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Peregrine Capital Management LLC (1.11%), Bank of Montreal Can (0.05%), Russell Investments Group Ltd. (0.03%), Gradient Investments LLC (0.01%), Quantitative Systematic Strategies LLC (0.01%) and Inspirion Wealth Advisors LLC (0.01%). Company insiders that own Nevro Corp. stock include Andre Walker, Andrew H Galligan, Brad Vale, Doug Alleavitch, Michael Enxing, Michael F Demane, Rami Elghandour and Wilfred E Jaeger. View Institutional Ownership Trends for Nevro Corp..
Who sold Nevro Corp. stock? Who is selling Nevro Corp. stock?
Nevro Corp.'s stock was sold by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd. and Creative Planning. Company insiders that have sold Nevro Corp. stock in the last year include Andrew H Galligan, Doug Alleavitch, Michael Enxing, Michael F Demane, Rami Elghandour and Wilfred E Jaeger. View Insider Buying and Selling for Nevro Corp..
Who bought Nevro Corp. stock? Who is buying Nevro Corp. stock?
Nevro Corp.'s stock was purchased by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, Gradient Investments LLC, Quantitative Systematic Strategies LLC, Bank of Montreal Can, Inspirion Wealth Advisors LLC and US Bancorp DE. View Insider Buying and Selling for Nevro Corp..
How do I buy Nevro Corp. stock?
Shares of Nevro Corp. can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Nevro Corp.'s stock price today?
One share of Nevro Corp. stock can currently be purchased for approximately $87.35.
MarketBeat Community Rating for Nevro Corp. (NYSE NVRO)MarketBeat's community ratings are surveys of what our community members think about Nevro Corp. and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Nevro Corp. (NYSE:NVRO) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Hold Rating, 8 Buy Ratings |
| Consensus Rating: | Buy (Score: 2.89) |
| Consensus Price Target: | $103.89 (18.93% upside) |
Analysts' Ratings History for Nevro Corp. (NYSE:NVRO)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 7/5/2017 | Canaccord Genuity | Reiterated Rating | Buy | $120.00 | High |  |
| 7/3/2017 | J P Morgan Chase & Co | Reiterated Rating | Overweight | $102.00 | Low | |
| 6/15/2017 | Northland Securities | Set Price Target | Buy | $96.00 | Low | |
| 5/14/2017 | B. Riley | Downgrade | Neutral | $85.00 | Low | |
| 2/24/2017 | Leerink Swann | Boost Price Target | Outperform | $100.00 -> $110.00 | N/A | |
| 8/11/2016 | Piper Jaffray Companies | Reiterated Rating | Overweight | $98.00 -> $112.00 | N/A | |
| 8/9/2016 | JMP Securities | Boost Price Target | Market Outperform | $90.00 -> $110.00 | N/A | |
| 8/9/2016 | BMO Capital Markets | Reiterated Rating | Buy | $100.00 | N/A | |
| 8/8/2016 | Bank of America Corporation | Initiated Coverage | Buy | $100.00 | N/A | |
| 7/18/2016 | William Blair | Reiterated Rating | Outperform | | N/A | |
| 7/12/2016 | Wells Fargo & Company | Initiated Coverage | Outperform | | N/A | |
| 6/29/2016 | Morgan Stanley | Reiterated Rating | Buy | $86.00 | N/A | |
| 5/16/2016 | Sterne Agee CRT | Reiterated Rating | Buy | | N/A | |
(Data available from 7/25/2015 forward)
Earnings History for Nevro Corp. (NYSE:NVRO)Earnings History by Quarter for Nevro Corp. (NYSE NVRO)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 5/8/2017 | Q1 2017 | ($0.26) | ($0.50) | $68.71 million | $68.40 million | View | Listen | |
| 2/23/2017 | Q416 | ($0.20) | ($0.34) | $66.41 million | $70.50 million | View | N/A | |
| 11/7/2016 | Q316 | ($0.39) | ($0.14) | $58.05 million | $60.92 million | View | Listen | |
| 8/8/2016 | Q216 | ($0.47) | ($0.31) | $45.11 million | $55.40 million | View | N/A | |
| 5/9/2016 | Q116 | ($0.65) | ($0.33) | $33.48 million | $41.65 million | View | N/A | |
| 2/29/2016 | Q415 | ($0.56) | ($0.51) | $32.88 million | $33.10 million | View | Listen | |
| 11/9/2015 | Q315 | ($0.75) | ($0.70) | $12.51 million | $15.40 million | View | N/A | |
| 8/6/2015 | Q215 | ($0.89) | ($0.77) | $9.65 million | $11.40 million | View | N/A | |
| 5/11/2015 | Q1 | ($0.54) | ($0.57) | $8.20 million | $9.66 million | View | Listen | |
| 3/18/2015 | Q4 2014 | ($0.51) | ($0.59) | | $9.72 million | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Nevro Corp. (NYSE:NVRO)Current Year EPS Consensus Estimate: $-1.02 EPS
Next Year EPS Consensus Estimate: $0.05 EPS
Dividend History for Nevro Corp. (NYSE:NVRO)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Nevro Corp. (NYSE:NVRO)Insider Ownership Percentage: 12.10%
Insider Trades by Quarter for Nevro Corp. (NYSE:NVRO)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 5/15/2017 | Andrew H. Galligan | CFO | Sell | 7,500 | $75.30 | $564,750.00 | |
| 5/2/2017 | Michael F Demane | Director | Sell | 29,800 | $96.07 | $2,862,886.00 | |
| 5/1/2017 | Rami Elghandour | CEO | Sell | 10,000 | $95.03 | $950,300.00 | |
| 4/4/2017 | Michael Enxing | VP | Sell | 1,500 | $93.53 | $140,295.00 | |
| 4/4/2017 | Michael F Demane | Director | Sell | 22,200 | $93.39 | $2,073,258.00 | |
| 4/3/2017 | Andrew H. Galligan | CFO | Sell | 30,000 | $94.46 | $2,833,800.00 | |
| 3/6/2017 | Michael Enxing | VP | Sell | 38,500 | $91.01 | $3,503,885.00 | |
| 3/3/2017 | Wilfred E Jaeger | Director | Sell | 43,980 | $95.03 | $4,179,419.40 | |
| 1/4/2017 | Michael Enxing | VP | Sell | 1,500 | $75.88 | $113,820.00 | |
| 12/5/2016 | Michael Enxing | VP | Sell | 1,500 | $76.38 | $114,570.00 | |
| 11/15/2016 | Andrew H Galligan | CFO | Sell | 7,500 | $86.90 | $651,750.00 | |
| 10/10/2016 | Rami Elghandour | CEO | Sell | 3,000 | $100.00 | $300,000.00 | |
| 10/6/2016 | Michael F Demane | Director | Sell | 139,514 | $97.46 | $13,597,034.44 | |
| 10/4/2016 | Michael Enxing | VP | Sell | 1,500 | $99.31 | $148,965.00 | |
| 8/22/2016 | Doug Alleavitch | VP | Sell | 3,000 | $100.00 | $300,000.00 | |
| 8/22/2016 | Wilfred E Jaeger | Director | Sell | 154,840 | $97.79 | $15,141,803.60 | |
| 8/17/2016 | Wilfred E Jaeger | Director | Sell | 155,160 | $97.31 | $15,098,619.60 | |
| 8/15/2016 | Andrew H Galligan | CFO | Sell | 7,500 | $97.71 | $732,825.00 | |
| 8/10/2016 | Doug Alleavitch | VP | Sell | 2,500 | $95.00 | $237,500.00 | |
| 8/9/2016 | Michael F Demane | Director | Sell | 26,667 | $91.50 | $2,440,030.50 | |
| 8/4/2016 | Michael Enxing | VP | Sell | 1,500 | $82.06 | $123,090.00 | |
| 7/29/2016 | Doug Alleavitch | VP | Sell | 1,000 | $85.00 | $85,000.00 | |
| 7/29/2016 | Michael F Demane | Director | Sell | 13,333 | $84.00 | $1,119,972.00 | |
| 7/11/2016 | Doug Alleavitch | VP | Sell | 2,000 | $80.00 | $160,000.00 | |
| 7/11/2016 | Michael F Demane | Director | Sell | 13,333 | $79.00 | $1,053,307.00 | |
| 7/5/2016 | Michael Enxing | VP | Sell | 1,500 | $75.39 | $113,085.00 | |
| 7/1/2016 | Michael F Demane | Director | Sell | 13,333 | $74.00 | $986,642.00 | |
| 6/8/2016 | Doug Alleavitch | VP | Sell | 1,000 | $75.00 | $75,000.00 | |
| 6/8/2016 | Rami Elghandour | CEO | Sell | 7,000 | $76.59 | $536,130.00 | |
| 6/6/2016 | Michael Enxing | VP | Sell | 1,500 | $73.29 | $109,935.00 | |
| 6/2/2016 | Andre Walker | VP | Sell | 4,000 | $73.50 | $294,000.00 | |
| 6/1/2016 | Doug Alleavitch | VP | Sell | 500 | $72.00 | $36,000.00 | |
| 5/18/2016 | Wilfred E Jaeger | Director | Sell | 112,983 | $64.68 | $7,307,740.44 | |
| 5/16/2016 | Andrew H Galligan | CFO | Sell | 10,000 | $64.78 | $647,800.00 | |
| 5/16/2016 | Michael F Demane | CEO | Sell | 39,999 | $64.77 | $2,590,735.23 | |
| 5/12/2016 | Rami Elghandour | President | Sell | 7,000 | $63.93 | $447,510.00 | |
| 5/4/2016 | Michael Enxing | VP | Sell | 1,500 | $65.06 | $97,590.00 | |
| 4/4/2016 | Michael Enxing | VP | Sell | 8,767 | $61.59 | $539,959.53 | |
| 4/1/2016 | Rami Elghandour | President | Sell | 7,000 | $60.99 | $426,930.00 | |
| 1/11/2016 | Andre Walker | VP | Sell | 7,987 | $70.75 | $565,080.25 | |
| 1/4/2016 | Doug Alleavitch | VP | Sell | 2,514 | $66.47 | $167,105.58 | |
| 12/17/2015 | Andre Walker | VP | Sell | 13 | $69.00 | $897.00 | |
| 12/7/2015 | Rami Elghandour | President | Sell | 3,500 | $61.82 | $216,370.00 | |
| 12/2/2015 | Andre Walker | VP | Sell | 1,000 | $64.00 | $64,000.00 | |
| 12/1/2015 | Andre Walker | VP | Sell | 8,000 | $59.50 | $476,000.00 | |
| 11/30/2015 | Andre Walker | VP | Sell | 6,000 | $58.50 | $351,000.00 | |
| 11/30/2015 | Rami Elghandour | President | Sell | 3,500 | $60.00 | $210,000.00 | |
| 11/24/2015 | Andre Walker | VP | Sell | 1,000 | $55.00 | $55,000.00 | |
| 11/23/2015 | Andre Walker | VP | Sell | 1,000 | $54.00 | $54,000.00 | |
| 11/23/2015 | Wilfred E Jaeger | Director | Sell | 25,000 | $53.48 | $1,337,000.00 | |
| 11/18/2015 | Wilfred E Jaeger | Director | Sell | 175,000 | $52.24 | $9,142,000.00 | |
| 11/16/2015 | Michael F Demane | CEO | Sell | 26,667 | $50.52 | $1,347,216.84 | |
| 11/13/2015 | Brad Vale | Director | Buy | 2,000 | $50.76 | $101,520.00 | |
| 9/17/2015 | Andre Walker | VP | Sell | 4,000 | $50.75 | $203,000.00 | |
| 9/2/2015 | Michael F Demane | CEO | Sell | 40,001 | $45.11 | $1,804,445.11 | |
| 6/8/2015 | & Johnson Johnson | Major Shareholder | Sell | 1,010,265 | $47.94 | $48,432,104.10 | |
| 6/8/2015 | Bay City Capital Llc | Insider | Sell | 491,835 | $47.94 | $23,578,569.90 | |
| 6/8/2015 | Wilfred E Jaeger | Director | Sell | 393,468 | $47.94 | $18,862,855.92 | |
| 11/12/2014 | & Johnson Johnson | Major Shareholder | Buy | 40,000 | $18.00 | $720,000.00 | |
| 11/12/2014 | A/S Novo | Insider | Buy | 215,000 | $18.00 | $3,870,000.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Nevro Corp. (NYSE:NVRO)
Latest Headlines for Nevro Corp. (NYSE:NVRO)
| Source: |
|
| Date | Headline |
|---|
 | Nevro to Report Operating Results for the Second Quarter 2017
finance.yahoo.com - July 25 at 6:18 AM |
 | Reviewing Bio-Rad Laboratories (BIO) and Nevro Corp. (NVRO)
www.americanbankingnews.com - July 22 at 8:04 AM |
| Nevro Corp. (NVRO) Upgraded to "Hold" at BidaskClub
www.americanbankingnews.com - July 16 at 10:50 PM |
 | Nevro Corp (NVRO) Shares Cross Above 200 DMA
www.nasdaq.com - July 14 at 7:01 AM |
 | Medical Equipment Stock Performance Review -- Nevro, EnteroMedics, Avinger, and ViewRay
www.prnewswire.com - July 13 at 7:32 AM |
| Nevro (NVRO) Surges: Stock Moves 11.4% Higher - Nasdaq
www.nasdaq.com - July 8 at 6:13 PM |
| ETFs with exposure to Nevro Corp. : July 7, 2017
finance.yahoo.com - July 8 at 1:12 PM |
| Nevro Corp. breached its 50 day moving average in a Bullish Manner : NVRO-US : July 6, 2017
finance.yahoo.com - July 7 at 7:47 AM |
| Health Care Sector Update for 07/05/2017: NVRO,MTBC,BGNE - Nasdaq
www.nasdaq.com - July 6 at 7:36 AM |
| BUZZ-U.S. STOCKS ON THE MOVE- Tesla, Diebold Nixdorf, Nevro ... - Nasdaq
www.nasdaq.com - July 6 at 7:36 AM |
| Here's Why Shares of Nevro Corp. (NVRO) Jumped Today - Nasdaq
www.nasdaq.com - July 6 at 7:36 AM |
| Here's Why Shares of Nevro Corp. (NVRO) Jumped Today
finance.yahoo.com - July 6 at 7:36 AM |
| Brokerages Anticipate Nevro Corp. (NVRO) Will Post Earnings of -$0.29 Per Share
www.americanbankingnews.com - July 5 at 2:12 PM |
| Canaccord Genuity Reaffirms Buy Rating for Nevro Corp. (NYSE:NVRO)
www.americanbankingnews.com - July 5 at 1:58 PM |
 | Why Nevro Corp. Is Soaring 10% Higher Today
www.fool.com - July 5 at 1:19 PM |
| Nevro Announces Preliminary Unaudited Second Quarter 2017 Revenue and Business Update - PR Newswire (press release)
www.prnewswire.com - July 5 at 9:03 AM |
| Nevro Announces Preliminary Unaudited Second Quarter 2017 Revenue and Business Update
finance.yahoo.com - July 5 at 9:03 AM |
| Nevro Corp. (NYSE:NVRO) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - July 3 at 10:40 AM |
| Nevro Corp. (NYSE:NVRO) Stock Rating Reaffirmed by J P Morgan Chase & Co
www.americanbankingnews.com - July 3 at 9:50 AM |
| ETFs with exposure to Nevro Corp. : June 26, 2017
finance.yahoo.com - June 27 at 6:47 AM |
| Nevro Corp. (NVRO) Given a $96.00 Price Target at Northland Securities
www.americanbankingnews.com - June 17 at 2:20 PM |
| ETFs with exposure to Nevro Corp. : June 16, 2017
finance.yahoo.com - June 16 at 7:55 PM |
 | Nevro (NVRO) SENZA-RCT 24-Month Outcomes Publication Selected by Neurosurgery as Top Pain Paper of the Year - StreetInsider.com
www.streetinsider.com - June 16 at 8:20 AM |
| Neurosurgery Selects the SENZA-RCT 24-Month Outcomes Publication as the Top Pain Paper of the Year
finance.yahoo.com - June 16 at 8:20 AM |
| Nevro Corp. :NVRO-US: Earnings Analysis: Q1, 2017 By the Numbers : June 14, 2017
finance.yahoo.com - June 14 at 4:10 PM |
| Brokerages Expect Nevro Corp (NVRO) Will Announce Quarterly Sales of $73.83 Million
www.americanbankingnews.com - June 11 at 8:56 AM |
| Zacks: Brokerages Anticipate Nevro Corp (NVRO) Will Post Earnings of -$0.29 Per Share
www.americanbankingnews.com - June 9 at 2:12 PM |
| Nevro Corp (NVRO) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - June 6 at 7:38 AM |
| Zacks Investment Research Lowers Nevro Corp (NVRO) to Sell
www.americanbankingnews.com - June 3 at 7:12 AM |
| Relative Strength Alert For Nevro
www.nasdaq.com - May 31 at 7:17 PM |
| Nevro to Present at the William Blair Growth Stock Conference
finance.yahoo.com - May 30 at 6:40 PM |
| Nevro Corp (NVRO) Downgraded by ValuEngine to Sell
www.americanbankingnews.com - May 24 at 3:56 PM |
| Zacks: Analysts Anticipate Nevro Corp (NVRO) Will Announce Quarterly Sales of $73.83 Million
www.americanbankingnews.com - May 17 at 12:02 PM |
| Nevro Corp (NVRO) CFO Sells $564,750.00 in Stock
www.americanbankingnews.com - May 16 at 7:33 PM |
| -$0.28 EPS Expected for Nevro Corp (NVRO) This Quarter
www.americanbankingnews.com - May 15 at 9:24 AM |
| B. Riley Downgrades Nevro Corp (NVRO) to Neutral
www.americanbankingnews.com - May 14 at 10:16 AM |
| Nevro Corp (NVRO) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - May 12 at 7:40 AM |
| Nevro Corp (NVRO) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - May 11 at 8:04 AM |
| Edited Transcript of NVRO earnings conference call or presentation 8-May-17 8:30pm GMT
finance.yahoo.com - May 10 at 11:59 AM |
| Oversold Conditions For Nevro (NVRO)
www.nasdaq.com - May 9 at 6:32 PM |
| Nevro Corp. Just Tumbled By As Much As 12% -- Here's Why
finance.yahoo.com - May 9 at 6:32 PM |
| Medtech Player Losses Double That Of Views; Shares Tumble
finance.yahoo.com - May 9 at 6:32 PM |
| Nevro Corp (NVRO) Releases Quarterly Earnings Results, Misses Expectations By $0.24 EPS
www.americanbankingnews.com - May 9 at 4:02 PM |
| Nevro Corp (NVRO) Rating Reiterated by Northland Securities
www.americanbankingnews.com - May 9 at 11:32 AM |
| B. Riley Downgrades Nevro Corp (NVRO) to Neutral Citing Slower US-Based Revenue Growth
www.streetinsider.com - May 9 at 11:26 AM |
| Nevro Reports First Quarter 2017 Financial Results
finance.yahoo.com - May 8 at 6:23 PM |
 | Nevro reports 1Q loss
marketbeat.com - May 8 at 4:34 PM |
| Medical Product Q1 Earnings on May 8: ITGR, OPK & More
finance.yahoo.com - May 5 at 7:13 PM |
| Nevro Corp (NVRO) Receives Media Impact Score of -0.08
www.americanbankingnews.com - May 4 at 12:08 PM |
| Rami Elghandour Sells 10,000 Shares of Nevro Corp (NVRO) Stock
www.americanbankingnews.com - May 3 at 7:00 PM |
Nevro Corp. (NVRO) Chart for Tuesday, July, 25, 2017
